Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: An opportunity to improve cardiovascular risk following kidney transplantation?

Transplant International

Volumn 24, Issue 1, 2011, Pages 30-42

  Zeier, Martin ^a   Van Der Giet, Markus ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

calcineurin inhibitors; cardiovascular; cardiovascular risk; everolimus; m TOR inhibitors; sirolimus

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GRAFT SURVIVAL; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; BLOOD PRESSURE; CALCINEURIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RISK; SIROLIMUS; TACROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 78650003866     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01140.x     Document Type: Review

References (127)

1. Ojo AO,. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82: 603.
2. Morales JM, Marcén R, Andrés A, et al. Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney Int 2008; 74 (Suppl. 111): S94.
3. Kasiske BL, Chakkera HA, Roel J,. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
4. Oliveras A, Roquer J, Puig JM, et al. Stroke in renal transplant recipients: epidemiology, predictive risk factors and outcome. Clin Transplant 2003; 17: 1.
5. Abbott KC, Hypolite IO, Hshieh P, Cruess D, Taylor AJ, Agodoa LY,. Hospitalized congestive heart failure after renal transplantation in the United States. Ann Epidemiol 2002; 12: 115.
6. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J,. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002; 13: 1084.
7. Foley RN, Parfrey PS, Sarnak MJ,. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 (12 Suppl.): S16.
8. Aakhus S, Dahl K, Wideroe TE,. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transplant 2004; 18: 596.
9. Matas AJ, Humar A, Gillingham KJ, et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 2002; 62: 704.
10. Cofán F, Vela E, Clèries M,. Catalan Renal Registry. Obesity in renal transplantation: analysis of 2691 patients. Transplant Proc 2005; 37: 3695.
11. Opelz G, Döhler B,. Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5: 2725.
12. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071.
13. Fellstrom B, Jardine AG, Soveri I, et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the assessment of Lescol in renal transplantation trial. Transplantation 2005; 79: 1160.
14. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P,. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003; 14: 462.
15. Djamali A, Becker YT, Simmons WD, Johnson CA, Premasathian N, Becker BN,. Increasing hematocrit reduces early posttransplant cardiovascular risk in diabetic transplant recipients. Transplantation 2003; 76: 816.
16. Lopez-Rocafort L, Brennan DC,. Current review of cytomegalovirus in renal transplantation. Minerva Urol Nefrol 2001; 53: 145.
17. Calne R,. Cyclosporine as a milestone in immunosuppression. Transplant Proc 2004; 36 (Suppl. 2S): 13S.
18. Kramer NC, Peters TG, Rohr MS, Thacker LR, Vaughn WK,. Beneficial effect of cyclosporine on renal transplantation. A multicenter long-term study. Transplantation 1990; 49: 343.
19. Hill CM, Douglas JF, Rajkumar KV, McEvoy J, McGeown MG,. Glycosuria and hyperglycemia after kidney transplantation. Lancet 1974; 2: 490.
20. Miller LW,. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002; 2: 807.
21. Moore R, Hernandez D, Valantine H,. Calcineurin inhibitors and post-transplant hyperlipidaemias. Drug Saf 2001; 24: 755.
22. Jindal RM, Zawada Jr ET,. Obesity and kidney transplantation. Am J Kidney Dis 2004; 43: 943.
23. Bouvier N, Flinois JP, Gilleron J, et al. Cyclosporine triggers endoplasmic reticulum stress in endothelial cells: a role for endothelial phenotypic changes and death. Am J Physiol Renal Physiol 2009; 296: F160.
24. Raymond MA, Mollica L, Vigneault N, et al. Blockade of the apoptotic machinery by cyclosporin A redirects cell death toward necrosis in arterial endothelial cells: regulation by reactive oxygen species and cathepsin D. FASEB J 2003; 17: 515.
25. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506.
26. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ,. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
27. Webster AC, Woodroff RC, Taylor RS, Chapman JR, Craig JC,. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. Br Med J 2005; 331: 810.
28. Asberg A, Midtvedt K, Voytovich MH, et al. Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation. Clin Transplant 2009; 23: 511.
29. Bodziak KA, Hricik De,. New-onset diabetes mellitus after solid organ transplantation. Transplant Int 2009; 22: 519.
30. Elmagd MM, Bakr MA, Metwally AH, Wahab AM,. Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant. Exp Clin Transplant 2008; 6: 42.
31. Gourishankar S, Jhangri GS, Tonelli M, Wales LH, Cockfield SM,. Development of diabetes mellitus following kidney transplantation: a Canadian experience. Am J Tranpslant 2004; 4: 1876.
32. Burroughs TE, Lentine KL, Takemoto SK, et al. Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. Clin J Am Soc Nephrol 2007; 2: 517.
33. Zhang R, Leslie B, Boudreaux JP, Frey D, Reisin E,. Hypertension after kidney transplantation: impact, pathogenesis and therapy. Am J Med Sci 2003; 325: 202.
34. Midtvedt K, Neumayer HH,. Management strategies for posttransplant hypertension. Transplantation 2000; 70 (11 Suppl.): SS64.
35. First MR, Neylan JF, Rocher LL, Tejani A,. Hypertension after renal transplantation. J Am Soc Nephrol 1994; 4 (Suppl. 1): S30.
36. Ducloux D, Motte G, Kribs M, et al. Hypertension in renal transplantation: donor and recipient risk factors. Clin Nephrol 2002; 57: 409.
37. Nankivell BJ, Borrows RJ, Fung CL-S, O'Connell PJ, Chapman JR, Allen RD,. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
38. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282.
39. Ekberg H, Tedesco-Silva H, Demirbas A, et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
40. Büchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522.
41. Durrbach A, Rostaing L, Tricot L, et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 2008; 85: 486.
42. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514.
43. Flechner SM, Kobashigawa J, Klintmalm G,. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1.
44. Ekberg H,. Calcineurin inhibitor sparing in renal transplantation. Transplantation 2008; 86: 761.
45. Augustine JJ, Hricik DE,. Minimization of immunosuppression in kidney transplantation. Curr Opin Nephrol Hypertens 2007; 16: 535.
46. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
47. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: CONCEPT Study. Am J Transplant 2009; 9: 1115.
48. Nashan B, Curtis J, Ponticelli C, et al. on behalf of the 156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year Phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332.
49. Budde K, Becker T, Sommerer C, et al. Analysis of renal function in everolimus/enteric-coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus study. Am J Transplant 2009; 9: 259. (Abstract 237).
50. Morales JM, Grinyó JM, Campistol JM, et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. Transplantation 2008; 86: 620.
51. Weir M, Mulgaonkar S, Pearson T, et al. Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2-year outcomes of the Spare-the-Nephron (STN) trial. Am J Transplant 2009; 9: 200. (Abstract 33).
52. Grinyo JM, Paul J, Novoa P, et al. Better renal function in renal-transplant recipients treated with everolimus plus CsA elimination compared with CsA reduction. Transp Int 2009; 22 (S2): 183.
53. Salvadori M, Budde K, Holzer H, et al. Upper everolimus blood levels with very low-dose cyclosporin: 12 months follow up of the EVEREST study. Am J Transplant 2009, 9: Abstract 1085.
54. Bertoni E, Larti A, Farsetti S, et al. Cyclosporine (CyA) very low dose with everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment with EC-MPS (M). Transpl Int 2009; 22 (S2): 91.
55. Tedesco-Silva H, Kim YS, Lackova E, et al. Everolimus with reduced-dose cyclosporine: results from a randomized study in 833 de-novo renal-transplant recipients. Transpl Int 2009; 22 (S2): 186.
56. Ruiz JC, Campistol JM, Grinyó JM, et al. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathological allograft lesions. Transplantation 2004; 78: 1312.
57. Castillo-Lugo JA, Vergne-Marini P,. Hypertension in kidney transplantation. Semin Nephrol 2005; 25: 252.
58. Morris ST, McMurray JJ, Rodger RS, Farmer R, Jardine AG,. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int 2000; 57: 1100.
59. Calo LA, Davis PA, Giacon B, et al. Oxidative stress in kidney transplant patients with calcineurin inhibitor induced hypertension: effect of ramapril. J Cardiovasc Pharmacol 2002; 40: 625.
60. Oflaz H, Turkman A, Kazancioglu R, et al. The effect of calcineurin inhibitors on endothelial function in transplant recipients. Clin Transplant 2003; 17: 212.
61. Reis F, Parada B, Teixeira deLemos E, et al. Hypertension induced by immunosuppressive drugs: a comparative analysis between sirolimus and cyclosporine. Transplant Proc 2009; 41: 868.
62. Mulay AV, Hussain N, Fergusson D, Knoll GA,. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005; 5: 1748.
63. Grinyo JM, Campistol JM, Paul J, et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 2004; 4: 1308.
64. Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004; 15: 228.
65. Pietruck F, Klempnauer J, Arns W, et al. Efficacy and safety of everolimus (RAD)/enteric-coated mycophenolate sodium (EC-MPS) after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final results of the ZEUS trial. Am J Transplant 2009; 9: Abstract 1093.
66. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22.
67. Baboolal K,. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 2003; 75: 1404.
68. Spagnoletti G, Citterio F, Favi E, et al. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine. Transplant Proc 2009; 41: 1175.
69. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025.
70. Wolff K, Fleming C, Hanifin J, et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br J Dermatol 2005; 152: 1296.
71. Brattström C, Wilczek H, Tydén G, et al. Hyperlipidemia inrenal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65: 1272.
72. Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036.
73. Webster AC, Lee VW, Chapman JR, Craig JC,. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234.
74. Blum CB,. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002; 2: 551.
75. Gonwa T, Mendez R, Yang HC, et al. Prograf Study Group. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003; 75: 1213.
76. Vítko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 1532.
77. Lorber MI, Mulgaonkar S, Butt KM, et al. B251 Study Group. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244.
78. Tedesco-Silva Jr H, Vitko S, Pascual J, et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007; 20: 27.
79. Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008; 85: 821.
80. Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588.
81. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC,. Posttrransplantation diabetes. Diabetes Care 2002; 25: 583.
82. Jindal RM, Sidner JA, Milgrom ML,. Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 1997; 16: 242.
83. Marchetti P, Navales R,. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 2000; 23: 482.
84. David-Neto E, Lemos FC, Fadel LM, et al. The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. Transplantation 2007; 84: 50.
85. Romagnoli J, Citterio F, Nanni G, et al. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 2006; 38: 1034.
86. Teutonico A, Schena PF, Di Paolo S,. Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128.
87. Roland M, Gatault P, Doute C, et al. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 2008; 21: 523.
88. Johnson O, Rose CL, Webster AC, Gill JS,. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411.
89. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.
90. Krämer BK, Neumayer H-H, Stahl R, et al. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab. Transplant Proc 2005; 37: 1601.
91. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY,. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296.
92. Roodnat JI, Mulder PG, Rischen-Vos J, et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001; 72: 438.
93. Alonso A, Oliver J,. Causes of death and mortality risk factors. Nephrol Dial Transplant 2004; 19: 38.
94. Van Den Akker JM, Wetzels JF, Hoitsma AJ,. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006; 70: 1355.
95. Martinez-Mier G, Avila-Pardo SF, Mendez-Lopez MT, Budar-Fernandez LF,. Long-term results after conversion from calcineurin inhibitors to sirolimus in renal transplant patients. Clin Transplant 2009 [Epub ahead of print].
96. Halim MA, Al-Otaibi T, Johny KV, et al. Long-term follow-up of 100 high-risk renal transplant recipients converted from calcineurin inhibitors to sirolimus: a single center experience. Transplant Proc 2009; 41: 1666.
97. Liew A, Chiang GS, Vathsala A,. Factors associated with proteinuria in renal transplant recipients treated with sirolimus. Transplant Int 2009; 22: 313.
98. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/ sirolimus in renal transplantation: three-year analysis. Transplantation 2006; 81: 845.
99. Rigatto C,. Anemia, renal transplantation and the anemia paradox. Simon Nephrol 2006; 26: 307.
100. Ersoy A, Baran B, Ersoy C, Kahvecioglu S, Akdag I,. Calcineurin inhibitors and post-transplant weight gain. Nephrology (Carlton) 2008; 13: 433.
101. Elster EA, Leeser DB, Morrissette C, et al. Obesity following kidney transplantation and steroid avoidance immunosuppression. Clin Transplant 2008; 22: 354.
102. Rogers CC, Alloway RR, Buell JF, et al. Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression. Transplantation 2005; 80: 26.
103. Ghahramani N, Reeves WB, Hollenbeak C,. Association between increased body mass index, calcineurin inhibitor use, and renal graft survival. 2008; 6: 199.
104. Rovira J, Marcelo Arellano E, Burke JT, et al. Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients. Transpl Int 2008; 21: 992.
105. Morice MC, Serrys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773.
106. Costa RA, Lansky AJ, Mintz GS, et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005; 95: 113.
107. Tsuchiya Y, Lansky AJ, Costa RA, et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 2006; 8: 464.
108. Marx SO, Marks AR,. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001; 104: 852.
109. Viklicky O, Zou H, Muller V, Lacha J, Szabo A, Heemann U,. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497.
110. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43: 1170.
111. Ma KL, Ruan XZ, Powis SH, et al. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol-Heart C 2007; 292: H2721.
112. Verheye S, Martinet W, Kockx MM, et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 2007; 49: 706.
113. -/- mice despite severe hypercholesterolemia. Atherosclerosis 2008; 198: 39.
114. Beatta R, Granata A, Canavesi M, et al. Everolimus inhibitors monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. J Pharmacol Exp Ther 2009; 328: 419.
115. Martinet W, Verheye S, De Meyer GR,. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy 2007; 3: 241.
116. Gouëffic Y, Potter-Perigo S, Chan CK, et al. Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM. Atherosclerosis 2007; 195: 23.
117. Pakala R, Stabile E, Jang GJ, et al. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharm 2005; 46: 481.
118. Waksman R, Pakala R, Burnett MS, et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc Radiat Med 2003; 4: 34.
119. Bahous SA, Blacher J, Safar ME,. Aortic stiffness, kidney disease and renal transplantation. Curr Hypertens Rep 2009; 11: 98.
120. Seckinger J, Sommerer C, Hinkel U-P, Hoffmann O, Zeier M, Schwenger V,. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 2008; 26: 2213.
121. DeLoach SS, Townsend RR,. Vascular stiffness: its measurement and significance for epidemiologic and outcome studies. Clin J Am Soc Nephrol 2008; 3: 184.
122. Paoletti E, Amidone M, Cassottana P, Gherzi M, Marsano L, Cannella G,. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis 2008; 52: 324.
123. Shioi T, McMullen JR, Tarnavski O, et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003; 107: 1664.
124. McMullen JR, Sherwood MC, Tarnavski O, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004; 109: 3050.
125. Gao XM, Wong G, Wang B, et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens 2006; 24: 1663.
126. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
127. Eisen HJ,. Long-term cardiovascular risk in transplantation-insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant 2006; 21 (Suppl. 3): 39.